- Home
- STRO vs TEI Comparison
STRO vs TEI Comparison
Compare STRO & TEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STRO | TEI |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | United States | United States |
| Employees | 131 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.0M | 313.6M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | STRO | TEI |
|---|---|---|
| Price | $9.92 | $6.31 |
| Analyst Decision | Hold | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $19.67 | N/A |
| AVG Volume (30 Days) | 121.9K | ★ 142.4K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.51% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $105,646,000.00 | N/A |
| Revenue This Year | $62.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.23 | $4.35 |
| 52 Week High | $21.50 | $5.39 |
Technical Indicators
Market Signals| Indicator | STRO | TEI |
|---|---|---|
| Relative Strength Index (RSI) | 78.91 | 39.01 |
| Support Level | $9.53 | $6.31 |
| Resistance Level | $10.10 | $6.43 |
| Average True Range (ATR) | 0.93 | 0.09 |
| MACD | 0.15 | -0.04 |
| Stochastic Oscillator | 98.52 | 0.00 |
Price Performance
Historical ComparisonAbout STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.